Fiduciary Group LLC Sells 105 Shares of McKesson Co. (NYSE:MCK)

Fiduciary Group LLC decreased its position in McKesson Co. (NYSE:MCK) by 5.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,814 shares of the company’s stock after selling 105 shares during the quarter. Fiduciary Group LLC’s holdings in McKesson were worth $840,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. U.S. Capital Wealth Advisors LLC raised its stake in shares of McKesson by 2.5% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,757 shares of the company’s stock worth $764,000 after acquiring an additional 43 shares during the last quarter. Valeo Financial Advisors LLC grew its holdings in McKesson by 6.8% during the third quarter. Valeo Financial Advisors LLC now owns 1,198 shares of the company’s stock valued at $521,000 after purchasing an additional 76 shares during the period. Avestar Capital LLC increased its stake in McKesson by 3.5% in the third quarter. Avestar Capital LLC now owns 1,579 shares of the company’s stock valued at $688,000 after purchasing an additional 53 shares in the last quarter. PDS Planning Inc raised its holdings in McKesson by 3.5% in the third quarter. PDS Planning Inc now owns 865 shares of the company’s stock worth $376,000 after purchasing an additional 29 shares during the period. Finally, Commonwealth Equity Services LLC boosted its position in shares of McKesson by 2.1% during the third quarter. Commonwealth Equity Services LLC now owns 61,484 shares of the company’s stock worth $26,737,000 after purchasing an additional 1,268 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total transaction of $92,256.00. Following the sale, the executive vice president now directly owns 1,511 shares in the company, valued at approximately $749,456. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the transaction, the chief executive officer now owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total transaction of $92,256.00. Following the sale, the executive vice president now directly owns 1,511 shares in the company, valued at approximately $749,456. The disclosure for this sale can be found here. Company insiders own 0.21% of the company’s stock.

McKesson Trading Up 0.6 %

NYSE MCK opened at $543.30 on Monday. The company has a market cap of $71.40 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 1.44 and a beta of 0.45. McKesson Co. has a 1-year low of $352.34 and a 1-year high of $544.81. The company has a 50 day moving average of $528.15 and a 200-day moving average of $489.95.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping the consensus estimate of $7.05 by $0.69. The firm had revenue of $80.90 billion during the quarter, compared to analysts’ expectations of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company earned $6.90 earnings per share. On average, equities research analysts forecast that McKesson Co. will post 27.59 earnings per share for the current year.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Monday, June 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Friday, May 31st. McKesson’s payout ratio is 11.24%.

Analysts Set New Price Targets

Several brokerages recently commented on MCK. Barclays initiated coverage on McKesson in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price objective on the stock. UBS Group increased their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Morgan Stanley upped their target price on shares of McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a research note on Monday, April 15th. StockNews.com raised shares of McKesson from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, Mizuho raised their target price on shares of McKesson from $450.00 to $505.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $533.50.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.